SGMO Sangamo Therapeutics Inc
Price (delayed)
$0.6532
Market cap
$146.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.49
Enterprise value
$129.62M
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.
Highlights
The EPS has surged by 67% year-on-year and by 34% since the previous quarter
Sangamo Therapeutics's net income has surged by 62% YoY and by 27% QoQ
The gross profit has shrunk by 67% YoY but it rose by 11% QoQ
The revenue has dropped by 67% year-on-year but it is up by 11% since the previous quarter
The equity has shrunk by 73% YoY and by 42% QoQ
The quick ratio has declined by 45% year-on-year and by 19% since the previous quarter
Key stats
What are the main financial stats of SGMO
Market
Valuations
Earnings
Shares outstanding
224.71M
Market cap
$146.78M
Enterprise value
$129.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.99
Price to sales (P/S)
2.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.24
Revenue
$57.8M
Gross profit
$57.8M
Operating income
-$103.97M
Net income
-$97.94M
EBIT
-$98.11M
EBITDA
-$88.75M
Free cash flow
-$67.41M
Per share
Balance sheet
Liquidity
EPS
-$0.49
EPS diluted
-$0.49
Free cash flow per share
-$0.33
Book value per share
$0.11
Revenue per share
$0.29
TBVPS
$0.5
Total assets
$101.64M
Total liabilities
$78.87M
Debt
$26.25M
Equity
$22.77M
Working capital
$5.89M
Debt to equity
1.15
Current ratio
1.13
Quick ratio
0.96
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
-153.5%
Gross margin
100%
Net margin
-169.4%
Operating margin
-179.9%
Return on assets
-90.1%
Return on equity
-275.3%
Return on invested capital
-184%
Return on capital employed
-175.7%
Return on sales
-169.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SGMO stock price
How has the Sangamo Therapeutics stock price performed over time
Intraday
14.58%
1 week
-22.7%
1 month
-35.96%
1 year
12.35%
YTD
-35.96%
QTD
-0.4%
Financial performance
How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$57.8M
Gross profit
$57.8M
Operating income
-$103.97M
Net income
-$97.94M
Gross margin
100%
Net margin
-169.4%
The gross profit has shrunk by 67% YoY but it rose by 11% QoQ
The revenue has dropped by 67% year-on-year but it is up by 11% since the previous quarter
Sangamo Therapeutics's net income has surged by 62% YoY and by 27% QoQ
The operating income has soared by 62% YoY and by 26% from the previous quarter
Growth
What is Sangamo Therapeutics's growth rate over time
Valuation
What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
5.99
P/S
2.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.24
The EPS has surged by 67% year-on-year and by 34% since the previous quarter
The price to book (P/B) is 80% higher than the 5-year quarterly average of 2.9 and 9% higher than the last 4 quarters average of 4.8
The equity has shrunk by 73% YoY and by 42% QoQ
The stock's P/S is 72% below its 5-year quarterly average of 7.0 and 59% below its last 4 quarters average of 4.9
The revenue has dropped by 67% year-on-year but it is up by 11% since the previous quarter
Efficiency
How efficient is Sangamo Therapeutics business performance
The ROE has plunged by 110% YoY and by 2.3% from the previous quarter
Sangamo Therapeutics's return on invested capital has decreased by 37% YoY but it has increased by 4.8% QoQ
The return on sales is up by 34% since the previous quarter but it has declined by 14% year-on-year
The company's return on assets rose by 17% QoQ
Dividends
What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SGMO.
Financial health
How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 29% greater than its total liabilities
The quick ratio has declined by 45% year-on-year and by 19% since the previous quarter
The company's current ratio fell by 43% YoY and by 16% QoQ
SGMO's debt is 15% higher than its equity
Sangamo Therapeutics's debt to equity has surged by 188% YoY and by 62% QoQ
The equity has shrunk by 73% YoY and by 42% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.